Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Primary Immunodeficiency Diseases × threonic acid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Primary Immunodeficiency Diseases 1 Neoplasms 1 Infections 1 Epstein-Barr Virus Infections 1

Interventions

AP 1903 reagent 2 threonic acid 1 fludarabine phosphate 1 fludarabine 1 Thiotepa 1 Tacrolimus 1 Methylprednisolone Hemisuccinate 1 Methylprednisolone 1 Melphalan 1 Magnesium Sulfate 1 Cyclophosphamide 1 Busulfan 1 Alemtuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02496676 2022-03-02

Magnesium Supplementation in People With XMEN Syndrome

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed

8 enrolled 7 charts

Primary Immunodeficiency Diseases, Infections, Neoplasms, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon ⚡